Michaela Feuring Buske

908 citations
5 papers · 732 indexed · 1 hit paper · h-index 3

Impact in

Papers in

Michaela Feuring Buske

5 papers receiving 700 citations

Hit Papers

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. 1998 · 724 citations
7241998202620072016200400600

Peers

Michaela Feuring Buske
Comparison fields: 5 of 51
  • Genetics 321
  • Pathology and Forensic Medicine 540
  • Oncology 345
  • Radiology, Nuclear Medicine and Imaging 198
  • Immunology 144
Replace C. Jonas with:
C. Jonas United States
David Wrench United Kingdom
W. Hiddemann Germany
K Blake United States
Niki Stavroyianni Greece
Theodora Papadaki Greece
Guiyuan Lei United Kingdom
D Crowther United Kingdom
Nedjad Losic United States
Matteo Dell’Olio Italy
Michaela Feuring Buske relative to C. Jonas United States C. Jonas's profile →
Citations per field
00.5×1.5×1.8×
C. Jonas · 1×
Citations per year

Countries citing papers authored by Michaela Feuring Buske

Since Specialization
Citations

This map shows the geographic impact of Michaela Feuring Buske's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaela Feuring Buske with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaela Feuring Buske more than expected).

Fields of papers citing papers by Michaela Feuring Buske

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michaela Feuring Buske. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaela Feuring Buske. The network helps show where Michaela Feuring Buske may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michaela Feuring Buske, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michaela Feuring Buske Line = papers co-authored together Michaela Feuring Buske links everyone, so they are left out of the graph.

All Works

5 of 5 papers shown
#Work
1 20132
2 20121
3 20084
4
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Hit paper breakdown →
1998724
5 19941

About Michaela Feuring Buske

Michaela Feuring Buske is a scholar working on Hematology, Pathology and Forensic Medicine, Immunology, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 5 papers that have together received 732 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (2 papers), Monoclonal and Polyclonal Antibodies Research (1 paper), CAR-T cell therapy research (1 paper), Immune Cell Function and Interaction (1 paper), Genomic variations and chromosomal abnormalities (1 paper), Lymphoma Diagnosis and Treatment (1 paper), Immunodeficiency and Autoimmune Disorders (1 paper) and Chromosomal and Genetic Variations (1 paper). The work is most often cited by research in Genetics (321 citations), Pathology and Forensic Medicine (540 citations), Oncology (345 citations), Radiology, Nuclear Medicine and Imaging (198 citations) and Immunology (144 citations). Michaela Feuring Buske has collaborated with scholars based in Germany and France. Frequent co-authors include Renaud Capdeville, Volker Diehl, F Reyes, Andreas Engert, Dengyan Ma, Nicolas Ketterer, Corinne Haïoun, H Tilly, John Radford and Peter Johnson. Their work appears in journals such as Blood and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026